Literature DB >> 11900240

Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.

Charles G Eberhart1, James L Kepner, Patricia T Goldthwaite, Larry E Kun, Patricia K Duffner, Henry S Friedman, Douglas R Strother, Peter C Burger.   

Abstract

BACKGROUND: Medulloblastomas are small cell embryonal tumors of the cerebellum found predominantly in children, only slightly more than half of whom survive. Predicting favorable outcome has been difficult, and improved stratification clearly is required to avoid both undertreatment and overtreatment. Patients currently are staged clinically, but no pathologic staging system is in use. Two rare subtypes at extreme ends of the histologic spectrum, i.e., medulloblastomas with extensive nodularity and large cell/anaplastic medulloblastomas, are associated with better and worse clinical outcomes, respectively. However, there is little data about correlations between histologic features and clinical outcome for most patients with medulloblastomas that fall between these histologic extremes of nodularity and anaplasia. Therefore, the authors evaluated the clinical effects of increasing anaplasia and nodularity in a large group of children with medulloblastomas, hypothesizing that increasing nodularity would predict better clinical outcomes and that increasing anaplasia would presage less favorable results.
METHODS: Medulloblastomas from 330 Pediatric Oncology Group patients were evaluated histologically with respect to extent of nodularity, presence of desmoplasia, grade of anaplasia, and extent of anaplasia. Pathologic and clinical data were then compared using Kaplan-Meier and log-rank analyses.
RESULTS: Increasing grade of anaplasia and extent of anaplasia were associated strongly with progressively worse clinical outcomes (P < 0.0001 for both). Significant anaplasia (moderate or severe) was identified in 24% of medulloblastoma specimens. Neither increasing degrees of nodularity nor desmoplasia were associated significantly with longer survival.
CONCLUSIONS: Moderate anaplasia and severe anaplasia were associated with aggressive clinical behavior in patients with medulloblastomas and were detected in a significant number of specimens (24%). Pathologic grading of medulloblastomas with respect to anaplasia may be of clinical utility.

Entities:  

Mesh:

Year:  2002        PMID: 11900240     DOI: 10.1002/cncr.10189

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  85 in total

1.  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.

Authors:  Regina I Jakacki; Peter C Burger; Tianni Zhou; Emiko J Holmes; Mehmet Kocak; Arzu Onar; Joel Goldwein; Minesh Mehta; Roger J Packer; Nancy Tarbell; Charles Fitz; Gilbert Vezina; Joanne Hilden; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.

Authors:  David W Ellison; Mehmet Kocak; James Dalton; Hisham Megahed; Meryl E Lusher; Sarra L Ryan; Wei Zhao; Sarah Leigh Nicholson; Roger E Taylor; Simon Bailey; Steven C Clifford
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

3.  Isochromosome 17q, MYC amplification and large cell/anaplastic phenotype in a case of medullomyoblastoma with extracranial metastases.

Authors:  Karen D Wright; Kendra von der Embse; Jamie Coleman; Zoltan Patay; David W Ellison; Amar Gajjar
Journal:  Pediatr Blood Cancer       Date:  2011-12-06       Impact factor: 3.167

Review 4.  Medulloblastoma: therapy and biologic considerations.

Authors:  Timothy R Gershon; Orren J Becher
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 5.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

6.  Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.

Authors:  Lauren E Hudson; Pia Mendoza; William H Hudson; Alison Ziesel; G Baker Hubbard; Jill Wells; Bhakti Dwivedi; Jeanne Kowalski; Sandra Seby; Viren Patel; Eldon Geisert; Charles Specht; Hans E Grossniklaus
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

Review 7.  Brain tumors in children.

Authors:  Andrew W Walter; Joanne M Hilden
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 8.  Aggressive infantile embryonal tumors.

Authors:  Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 9.  Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.

Authors:  Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Medulloblastoma in children: a 32-year experience from a single institution.

Authors:  Canan Akyüz; Ali Varan; Serhan Küpeli; Nejat Akalan; Figen Söylemezoglu; Faruk Zorlu; Tezer Kutluk; Münevver Büyükpamukçu
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.